Published on April 27, 2017

First Xarelto federal bellwether trial beginning in Louisiana

First Xarelto federal bellwether trial beginning in Louisiana’s Complex Litigation Center is also expected to see its first trial this year.

Plaintiffs charge Xarelto manufacturers with failing to properly warn patients that Xarelto use presented increased risks for cranial and gastrointestinal …

Full article

J&J, Bayer Accused of Hiding Xarelto Dangers in First Trial Boudreaux took Xarelto to help cut his stroke risk, but instead the drug caused serious gastrointestinal bleeding, according to his lawsuit.

Boudreaux spent a week in the intensive care unit and needed several blood transfusions and heart …

See the DrugWatch article

J&J, Bayer Accused of Hiding Blood-Thinning Drug’s Flaws Boudreaux says taking Johnson & Johnson’s blood-thinning drug Xarelto was one of the biggest mistakes of his life.

While Xarelto was supposed to help cut his stroke risk, Boudreaux says it instead caused internal bleeding that required a week …

Original Bloomberg post

First Xarelto Case to Test Views Over Attorney Ads Judiciary Committee Chairman Bob Goodlatte, who co-authored a tort reform bill that the U.S. House of Representatives passed last month, referenced the Xarelto litigation in letters last month calling on the American Bar Association and various …

National Law Journal has the full story

Pharmaceutical companies seeking to ascertain if third-party funding in Xarelto litigation their motion, Xarelto manufacturers asked if any third-party “has the right to control or be consulted about the plaintiffs’ litigation and whether there is a third-party source of funding for the plaintiffs’ litigation”, in addition to seeking the …

Full Penn Record article

Defendants on Philadelphia Xarelto Mass Tort Seek Disclosure of Third-Party Funding, PA
As the Philadelphia Xarelto mass tort moves closer towards the bellwether trial stage, Xarelto principles Bayer AG and Janssen Pharmaceuticals have signaled that they want to know the identity of any third-party funders associated with …

Full article


Leave a Comment

Your email address will not be published. Required fields are marked *